Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Last trade$0.65
Day change+$0.019 (+3.01%)
Day range$0.639 – $0.703
Volume115,790
Market cap$27M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$26.47M
Price / earnings
—
Price / book
3.24×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.43×
Profitability
Earnings per share
-$0.74
Return on assets
-378.35%
Return on equity
-380.24%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
200.08×
Quick ratio
200.08×
Cash ratio
88.42×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.64M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MIRA, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$450.33K
$578.7K
$5.33M
$904.35K
$1.05M
$1.49M
$1.58M
$1.01M
Research and development
$705.79K
$524.78K
$496.54K
$412.64K
$496.2K
$314.4K
$861.44K
$1.07M
Total operating expenses
$1.16M
$1.1M
$5.82M
$1.32M
$1.55M
$1.81M
$2.44M
$2.08M
Operating income
-$1.16M
-$1.1M
-$5.82M
-$1.32M
-$1.55M
-$1.81M
-$2.44M
-$2.08M
Interest expense
$0
$0
$53.17K
$15.7K
$0
$0
$38.11K
$37.75K
Income before taxes
-$1.21M
-$1.15M
-$5.98M
-$1.14M
-$1.54M
-$1.78M
-$2.4M
-$2.04M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.21M
-$1.15M
-$5.98M
-$1.14M
-$1.54M
-$1.78M
-$2.4M
-$2.04M
Net income attributable to common shareholders
-$1.21M
-$1.15M
-$5.98M
-$22.69M
-$1.54M
-$1.78M
-$2.4M
-$2.04M
EBITDA
-$1.16M
-$1.1M
-$5.82M
-$1.32M
-$1.55M
-$1.81M
-$2.44M
-$2.08M
Basic earnings per share
-$0.03
-$0.03
-$0.14
-$1.18
-$0.09
-$0.11
-$0.14
-$0.14
Diluted earnings per share
-$0.03
-$0.03
-$0.14
-$1.18
-$0.09
-$0.11
-$0.14
-$0.14
Recent news
Company coverage with links to the original publishers.
Mira Pharmaceuticals saw significant after-hours stock price increase following preclinical data announcement for Mira-55, a non-psychotropic marijuana compound that demonstrated superior pain reduction compared to morphine in animal studies.
Over 50 companies are advancing cannabinoid drug research, exploring potential treatments for mental health disorders, neurodegenerative diseases, and chronic inflammation, with promising clinical trials targeting conditions like Alzheimer's, pain management, and epilepsy.
Mira Pharmaceuticals has approved the acquisition of SKNY Pharmaceuticals, creating a combined enterprise value of over $60 million. The deal is expected to bring together the companies' pipelines and market opportunities.
KernelDAO, a top restaking protocol, has partnered with Mira, a pioneer in trustless verified AI technology, to launch a first-of-its-kind API that enhances AI reliability through trustless verification. The partnership aims to address key challenges in the AI industry, including reducing system downtime and errors through trustless verification.
Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announced that it is possibly considering an offer for the company.
MariaDB shares jumped 100.4% to $0.4530 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers
Destiny Tech100 Inc (NASDAQ: DXYZ) rose 52.9% to $13.76 in pre-market trading after gaining 9% on Tuesday.
PaySign, Inc. (NASDAQ: PAYS) gained 25.2% to $4.23 in pre-market trading after the company announced better-than-expected fourth-quarter results.
Hitek Global Inc. (NASDAQ: HKIT) gained 19.1% to $1.69 in pre-market trading.
The ONE Group Hospitality, Inc. (NASDAQ: STKS) shares rose 13.2% to $4.54 in pre-market trading after the company announced that it will acquire Safflower Holdings.
nCino, Inc. (NASDAQ: NCNO) gained 11.7% to $33.72 in pre-market trading as the company reported better-than-expected fourth-quarter results and issued FY25 adjusted earnings guidance above estimates..
Nuvation Bio Inc. (NASDAQ: NUVB) shares rose 11.5% to $3.21 in pre-market trading. Nuvation Bio shares gained 28% on Tuesday after BTIG upgraded the stock from Neutral ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.